Larimar Therapeutics
LRMR
69 hedge funds and large institutions have $46.8M invested in Larimar Therapeutics in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 22 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 20
0.26% less ownership
Funds ownership: 4.32% → 4.06% (-0.26%)
14% less funds holding
Funds holding: 80 → 69 (-11)
29% less capital invested
Capital invested by funds: $66.1M → $46.8M (-$19.3M)
50% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 22
63% less call options, than puts
Call options by funds: $55K | Put options by funds: $148K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$2.37M |
| 2 |
Renaissance Technologies
New York
|
+$1.14M |
| 3 |
Millennium Management
New York
|
+$1.1M |
| 4 |
Goldman Sachs
New York
|
+$794K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$600K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.09M |
| 2 |
JP Morgan Chase
New York
|
-$2.31M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.61M |
| 4 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$1.41M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$770K |
LRMR Hedge Fund Activity: Q2 2017 in Review
69 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q2 2017, worth a combined $46.8M — down 29% from $66.1M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of LRMR and 11 opened new positions — a net loss of 11 holders — while 20 trimmed existing stakes and 25 added.
The largest buyer was 683 Capital Management, adding an estimated $2.37M. The largest seller was BlackRock, cutting an estimated $4.09M.
- 69 institutional investors held Larimar Therapeutics (LRMR) as of Q2 2017, down from 80 in Q1 2017.
- Funds reported $46.8M of Larimar Therapeutics stock for Q2 2017, down 29% quarter-over-quarter.
- 11 funds opened new Larimar Therapeutics positions in Q2 2017 and 22 closed out, a net change of -11 holders.
- The largest Larimar Therapeutics buyer in Q2 2017 was 683 Capital Management, an estimated $2.37M added.
- The largest Larimar Therapeutics seller in Q2 2017 was BlackRock, an estimated $4.09M sold.
Based on aggregated 13F filings for Q2 2017.